Search Within

Michael John Mauro

Formats
  1. Meeting Abstract (188)
  2. Journal Article (67)
  3. Review (8)
  4. Correspondence (4)
  5. Research Letter (3)
  6. Book Section (2)
  7. Editorial (2)
  8. Guidelines (2)
Groups
  1. Adult Leukemia (276)
  2. Center for Hematologic Malignancies (276)
  3. Department of Medicine (276)
  4. Hematologic Malignancies, Division of (276)
  5. Biostatistics Service (10)
  6. Epidemiology and Biostatistics (10)

More Groups

People
  1. Raajit Rampal (12)
  2. Ellin Berman (8)
  3. Eytan Stein (8)
  4. Martin Tallman (7)
  5. Amber King (6)
  6. Andriy Derkach (6)

More People

Years
  1. 2025 (7)
  2. 2024 (17)
  3. 2023 (26)
  4. 2022 (33)
  5. 2021 (21)
  6. 2020 (26)

More Years

Publications
  1. Blood (97)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Journal of Clinical Oncology (22)
  4. Haematologica (21)
  5. Leukemia (12)
  6. American Journal of Hematology (8)

More Publications

Publishers
  1. American Society of Hematology (101)
  2. Elsevier Inc. (47)
  3. American Society of Clinical Oncology (22)
  4. Ferrata Storti Foundation (21)
  5. Nature Publishing Group (13)
  6. John Wiley & Sons (8)

More Publishers

Results (276)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term cardiac, vascular and hypertensive safety of bosutinib in patients with Philadelphia chromosome-positive (Ph+) leukemia resistant or intolerant to prior therapy
    Meeting Abstract

    Cortes, J. E.; Kim, D. W.; Kantarjian, H. M.; Mauro, M. J.; Aguiar, J. M.; An, F.; Leip, E.; Gambacorti-Passerini, C.; Brummendorf, T. H.
    Blood (2017)

    Fulltext@MSK | Save
  • Changes in RT-qPCR levels during and after TKI interruptions for attempted conceptions in women with CML
    Meeting Abstract

    Caldwell, L.; Claudiani, S.; Milojkovic, D.; Szydlo, R.; Abruzzese, E.; Nesr, G.; Mauro, M. J.; Palanicawander, R.; Gatenby, A.; Sabli, I.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Efficacy and safety outcomes by baseline comorbidity and age in patients newly diagnosed with chronic myeloid leukemia in chronic phase (CML-CP) and treated with dasatinib or imatinib in DASISION
    Meeting Abstract

    Mauro, M. J.; Cortes, J. E.; Hochhaus, A.; Shah, N. P.; Atallah, E.; Abaskharoun, M.; Sy, O.; Saglio, G.
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save
  • Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
    Journal Article

    Barber, M. C.; Mauro, M. J.; Moslehi, J.
    Hematology-American Society of Hematology Education Program (2017)

    Fulltext@MSK | Save
  • Ponatinib-induced ichthyosiform drug eruption: Insights into acquired ichthyosis
    Journal Article

    Xu, H.; Busam, K. J.; Mauro, M. J.; Markova, A.
    Dermatology Online Journal (2017)

    Fulltext@MSK | Save
  • Bosutinib (BOS) vs imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial
    Meeting Abstract

    Brümmendorf, T. H.; Gambacorti-Passerini, C.; Deininger, M.; Mauro, M. J.; Chuah, C.; Kim, D. W.; Le Coutre, P.; Jentsch-Ullrich, K.; Waller, C.; Wolf, D.; more...
    Oncology Research and Treatment (2017)

    Fulltext@MSK | Save
  • First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY
    Journal Article

    Goldberg, S. L.; Cortes, J. E.; Gambacorti-Passerini, C.; Hehlmann, R.; Khoury, H. J.; Michallet, M.; Paquette, R. L.; Simonsson, B.; Zyczynski, T.; Foreman, A.; more...
    American Journal of Hematology (2017)

    Fulltext@MSK | Save
  • Five-year efficacy and safety of dasatinib and imatinib by baseline comorbidity and age in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) from DASISION
    Meeting Abstract

    Mauro, M. J.; Cortes, J. E.; Hochhaus, A.; Shah, N. P.; Atallah, E. L.; Abaskharoun, M.; Sy, O.; Saglio, G.
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save
  • Oral asciminib (ABL001) vs bosutinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who received ≥ 2 prior tyrosine kinase inhibitors (TKIs): A multicenter, open-label, randomized, phase 3 study
    Meeting Abstract

    Mauro, M.; Boquimpani, C.; Minami, Y.; Réa, D.; Kemp, C.; Hsu Schmitz, S. F.; Gopalakrishna, P.; Hochhaus, A.
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save
  • Bosutinib (BOS) vs imatinib (IM) for newly diagnosed chronic myeloid leukemia (CML): Initial results from the BFORE trial
    Meeting Abstract

    Cortes, J.; Gambacorti-Passerini, C.; Deininger, M.; Mauro, M.; Chuah, C.; Kim, D. W.; Reilly, L.; Jeynes-Ellis, A.; Leip, E.; Bardy-Bouxin, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2017)

    Fulltext@MSK | Save